Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 8, 2012, Pages 1191-1203

  Sheppard, Dawn ^a   Bredeson, Christopher ^a   Allan, David ^a   Tay, Jason ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Hematopoietic stem cell transplantation; Mobilization strategy; Plerixafor; Stem cell mobilization

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR; RITUXIMAB;

ADD ON THERAPY; ADVERSE OUTCOME; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CD34 SELECTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FATALITY; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL MOBILIZATION; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIGENS, CD34; CYCLOPHOSPHAMIDE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84864002919     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.01.008     Document Type: Article

References (75)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome 1996, 335:91-97.
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
4. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
5. Demirer T., Buckner C.D., Gooley T., et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:937-941.
6. Perea G., Sureda A., Martino R., et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001, 80:592-597.
7. Kuittinen T., Nousiainen T., Halonen P., Mahlamäki E., Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:907-912.
8. Akhtar S., Weshi A.E., Rahal M., et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008, 49:769-778.
9. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
10. Gratwohl A., Baldomero H., Schmid O., Horisberger B., Bargetzi M., Urbano-Ispizua A. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant 2005, 36:575-590.
11. Gertz M.A. Current status of stem cell mobilization. Br J Haematol 2010, 150:647-662.
12. Watanabe H., Watanabe T., Suzuya H., et al. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Bone Marrow Transplant 2006, 37:661-668.
13. Meldgaard Knudsen L., Jensen L., Gaarsdal E., Nikolaisen K., Johnsen H.E. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 2000, 26:717-722.
14. Toor A.A., van Burik J.A., Weisdorf D.J. Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 2001, 28:1129-1134.
15. Fitoussi O., Perreau V., Boiron J.M., et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001, 27:837-842.
16. Hiwase D.K., Bollard G., Hiwase S., Bailey M., Muirhead J., Schwarer A.P. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007, 9:539-547.
17. Deliliers G.L., Annaloro C., Marconi M., et al. Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymphoma 2002, 43:1957-1960.
18. Pavone V., Gaudio F., Guarini A., et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002, 29:285-290.
19. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
20. Hatse S., Princen K., Bridger G., De Clercq E., Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
21. Rosenkilde M.M., Gerlach L.O., Hatse S., et al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 2007, 282:27354-27365.
22. Flomenberg N., Devine S.M., Dipersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
23. Liles W.C., Rodger E., Broxmeyer H.E., et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
24. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. PRISMA Group.
25. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
26. Schulz K.F., Grimes D.A. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002, 359:614-618.
27. Quittet P., Ceballos P., Lopez E., et al. Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients. Bone Marrow Transplant 2006, 38:275-284.
28. Ahn J.S., Park S., Im S.A., et al. High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization. Korean J Intern Med 2005, 20:224-231.
29. Hart C., Grassinger J., Andreesen R., Hennemann B. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. Bone Marrow Transplant 2009, 43:197-206.
30. Ataergin S., Arpaci F., Turan M., et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008, 83:644-648.
31. Copelan E., Pohlman B., Rybicki L., et al. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009, 43:101-105.
32. Demirer T., Ayli M., Ozcan M., et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002, 116:468-474.
33. Demuynck H., Delforge M., Verhoef G., Zachée P., Vandenberghe P., Boogaerts M. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995, 90:384-392.
34. Hohaus S., Martin H., Wassmann B., et al. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998, 22:625-630.
35. Shi Y.K., He X.H., Han X.H., et al. [Mobilization of autologous peripheral blood stem cells with etoposide and recombinant human granulocyte colony stimulating factor in malignant tumor patients]. [Article in Chinese]. Zhonghua Zhong Liu Za Zhi 2004, 26:360-363.
36. Spitzer G., Adkins D., Mathews M., et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997, 20:921-930.
37. Stiff P., Gingrich R., Luger S., et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000, 26:471-481.
38. Weaver C.H., Schulman K.A., Wilson-Relyea B., Birch R., West W., Buckner C.D. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000, 18:43-53.
39. André M., Baudoux E., Bron D., et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003, 43:50-57.
40. Arora M., Burns L.J., Barker J.N., et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004, 10:395-404.
41. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
42. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
43. Facon T., Harousseau J.L., Maloisel F., et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999, 94:1218-1225.
44. Gazitt Y., Callander N., Freytes C.O., et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res 2000, 9:737-748.
45. Kim S., Kim H.J., Park J.S., et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005, 84:742-747.
46. Kopf B., De Giorgi U., Vertogen B., et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 2006, 38:407-412.
47. Martinez E., Sureda A., De Dalmases C.D., et al. Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma. Bone Marrow Transplant 1996, 18:1-7.
48. Vela-Ojeda J., Tripp-Villanueva F., Montiel-Cervantes L., et al. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant 2000, 25:1141-1146.
49. Weaver C.H., Zhen B., Schartzberg L., Walker C., Upton S., Buckner C.D. A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide, and granulocyte colony-stimulating factor with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. Am J Clin Oncol 1998, 21:408-412.
50. Narayanasami U., Kanteti R., Morelli J., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
51. Min Y.J., Kim S.W., Suh C., et al. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J Korean Med Sci 2000, 15:49-52.
52. Ozcelik T., Topcuoglu P., Beksac M., et al. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF. Bone Marrow Transplant 2009, 44:779-783.
53. Weisdorf D., Miller J., Verfaillie C., et al. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. Biol Blood Marrow Transplant 1997, 3:217-223.
54. Boeve S., Strupeck J., Creech S., Stiff P.J. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004, 33:997-1003.
55. Perseghin P., Terruzzi E., Dassi M., et al. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009, 41:33-37.
56. Fietz T., Rieger K., Dimeo F., Blau I.W., Thiel E., Knauf W.U. Stem cell mobilization in multiple myeloma patients: do we need an age-adjusted regimen for the elderly?. J Clin Apher 2004, 19:202-207.
57. Canales M.A., Fernández-Jiménez M.C., Martín A., et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001, 86:494-498.
58. Laszlo D., Galieni P., Raspadori D., Tozzi M., Lauria F., Martinelli G. Fludarabine combination regimen severely affected peripheral blood stem cell mobilization. Acta Haematol 2004, 111:228-229.
59. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
60. Olivieri A., Marchetti M., Lemoli R., et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2011, [Epub ahead of print].
61. Duong H.K., Bolwell B.J., Rybicki L., et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. J Clin Apher 2011, 26:111-115.
62. Abhyankar S., Dejarnette S., Aljitawi O., Ganguly S., Merkel D., McGuirk J. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2011, [Epub ahead of print].
63. Costa L.J., Miller A.N., Alexander E.T., et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011, 46:523-528.
64. Li J., Hamilton E., Vaughn L., et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011, 51:2175-2182.
65. Vishnu P., Roy V., Paulsen A., Zubair A.C. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012, 52:55-62.
66. Shaughnessy P., Islas-Ohlmayer M., Murphy J., et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011, 17:729-736.
67. Dugan M.J., Maziarz R.T., Bensinger W.I., et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2011, 45:39-47.
68. Attolico I., Pavone V., Ostuni A., et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2011, 18:241-249.
69. Gazitt Y., Shaughnessy P., Lui Q. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell 2001, 10:167-176.
70. DiPersio J., Ho A., Hanrahan J., Hsu F., Fruehauf F. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011, 17:943-955.
71. Moog R. Mobilization and harvesting of peripheral blood stem cells. Curr Stem Cell Res Ther 2006, 1:189-201.
72. Porrata L.F., Markovic S.N. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med 2004, 4:78-85.
73. Dingli D., Nowakowski G.S., Dispenzieri A., et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006, 6:384-388.
74. Ramirez P., Rettig M.P., Uy G.L., et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114:1340-1343.
75. Herbert K.E., Walkley C.R., Winkler I.G., et al. Granulocyte colony-stimulating factor and an RARalpha specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells. Transplantation 2007, 83:375-384.